Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jun 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a combination of two medications, dexmedetomidine and esketamine, to help patients in the Intensive Care Unit (ICU) who are on mechanical ventilation. Patients in the ICU often experience anxiety, sleep problems, and a condition called delirium, which can affect their recovery. The researchers believe that using both medications together might help improve pain relief and sleep quality while also reducing the chances of delirium, ultimately helping patients recover better and breathe easier.

To participate in this trial, individuals must be at least 18 years old, be receiving mechanical ventilation in the ICU for a minimum of 24 hours, and need sedation as determined by their doctors. However, there are certain exclusions, such as those who are pregnant, have specific medical conditions, or cannot communicate effectively. If someone is eligible and chooses to participate, they can expect to receive a carefully monitored treatment that aims to enhance their comfort and recovery during a challenging time. It’s important to note that this trial is not yet recruiting participants, so those interested will need to wait for more information on when that will begin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged ≥18 years;
• • 2. Receiving invasive or non-invasive mechanical ventilation in the ICU, with an expected duration ≥24 hours;
• • 3. Require sedation as judged by ICU physicians.
• Exclusion Criteria:
• • 1. Pregnant or lactating women;
• • 2. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;
• • 3. Unable to communicate due to coma, severe dementia, or language barrier prior to invasive/non-invasive mechanical ventilation;
• • 4. After stroke, hypoxic encephalopathy, traumatic brain injury, or neurosurgery;
• • 5. Comorbid with hyperthyroidism or pheochromocytoma;
• • 6. Left ventricular ejection fraction \<30%, sick sinus syndrome, severe sinus bradycardia (heart rate \<50 bpm), second-degree or higher atrioventricular block without a pacemaker, or systolic blood pressure \<90 mmHg despite use of vasopressors;
• • 7. Severe liver dysfunction (Child-Pugh Class C), severe renal dysfunction (requiring dialysis), or expected survival ≤24 hours;
• • 8. Allergy to dexmedetomidine and/or esketamine, or any other conditions that are considered unsuitable for study participation.